financetom
Business
financetom
/
Business
/
Wynn Resorts Stock Dips On Q2 Results: Details
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wynn Resorts Stock Dips On Q2 Results: Details
Aug 6, 2024 2:05 PM

Wynn Resorts, Limited ( WYNN ) shares are trading lower after the company reported its second-quarter financial results Tuesday. Here's a look at the key figures for the quarter.

The Details: Wynn Resorts ( WYNN ) reported quarterly earnings of $1.12 per share on revenue of $1.733 billion with both figures missing the analyst consensus estimates.

For the second quarter of 2024, operating revenues increased by $79.7 million, $35.7 million, $50.6 million at Wynn Palace, Wynn Macau and the Las Vegas Operations, respectively, and decreased $9.3 million at Encore Boston Harbor, from the second quarter of 2023.

Read Also: What’s Going On With ZoomInfo Stock After Earnings?

The company’s board of directors declared a cash dividend of 25 cents per share, payable on Aug. 30, 2024, to stockholders of record as of Aug.t 19, 2024.

“Our second quarter results, including a new second-quarter record for Adjusted Property EBITDAR, reflect continued strength throughout our business. I am incredibly proud of our teams in Las Vegas, Macau and Boston,” said Craig Billings, CEO of Wynn Resorts, Limited ( WYNN ).

“Importantly, we continue to invest in growing the business, with construction on Wynn Al Marjan Island in the UAE progressing at a rapid pace. During the quarter, we also finalized a transaction to acquire our pro-rata share of the land on Al Marjan Island Three, including a sizable land bank for potential future development opportunities for Wynn Resorts ( WYNN ) or for selected third parties complementary to Wynn Al Marjan.”

WYNN Price Action: According to Benzinga Pro, Wynn Resorts ( WYNN ) shares are down 0.84% after-hours at $74.65 at the time of publication Tuesday.

Read Next: 

Hims & Hers Health Reports Better-Than-Expected Q2 Results: Details

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TScan Therapeutics' Potential Blood Cancer Therapies Receive FDA Regenerative Medicine Status
TScan Therapeutics' Potential Blood Cancer Therapies Receive FDA Regenerative Medicine Status
May 29, 2024
08:15 AM EDT, 05/29/2024 (MT Newswires) -- TScan Therapeutics ( TCRX ) said Wednesday it has received the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for its blood malignancy treatment candidates TSC-100 and TSC-101. The company said TSC-100 and TSC-101 are the lead therapy candidates in its heme malignancies program aimed at treating patients with acute myeloid...
Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3
Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3
May 29, 2024
08:14 AM EDT, 05/29/2024 (MT Newswires) -- Immunocore Holdings ( IMCR ) said Wednesday a phase 2/3 trial evaluating its therapy candidate, Kimmtrak as a monotherapy and in combination with pembrolizumab to treat certain patients with skin cancer has been converted into a phase 3 trial. The decision comes following a consultation with the US Food and Drug Administration, the...
Redwire Forms Coalition to Support Research Projects, AI in Space Operations
Redwire Forms Coalition to Support Research Projects, AI in Space Operations
May 29, 2024
08:14 AM EDT, 05/29/2024 (MT Newswires) -- Redwire ( RDW ) said Wednesday it has formed a coalition that will fund research projects focusing on using artificial intelligence in space operations. Redwire ( RDW ) is one of the two corporate sponsors of the Center for AEroSpace Autonomy Research, or CAESAR, at Stanford University, which aims to leverage various disciplines...
Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia
Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia
May 29, 2024
08:10 AM EDT, 05/29/2024 (MT Newswires) -- Milestone Pharmaceuticals ( MIST ) said Wednesday that the US Food and Drug Administration has accepted its New Drug Application for Cardamyst nasal spray for the management of paroxysmal supraventricular tachycardia, or PSVT, a type of arrhythmia or abnormal heart rhythm. The company said the regulator's Prescription Drug User Fee Act target date...
Copyright 2023-2026 - www.financetom.com All Rights Reserved